DPP4 and type 2 diabetes mellitus: Since its launch in 2006 by Merck, sitagliptin phosphate monohydrate, the first DPP-4 inhibitor (dipeptidyl peptidase 4), has been one of the best-selling orally active and safe agents for the treatment of T2DM (type 2 diabetes mellitus) [1,2,3].